BECN1 and hepatocellular carcinoma: Inhibition of the PERK-ATF4 pathway may further reduce the expression of Beclin1, an important protein involved in autophagy, thus, increasing the sensitivity of sorafenib to HCC cells by inhibiting autophagy [26].